Related and Nonrelated Parties [Axis] Nonrelated Party [Member] Related Party [Member] Class of Stock [Axis] Series D Convertible Preferred Stock [Member] Series D-1 Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Series D Preferred Stock [Member] Series D-1 Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Convertible Preferred Stock [Member] 2021 Unsecured Convertible Notes and Accrued Interest [Member] 2022 Unsecured Convertible Notes and Accrued Interest [Member] 2023 Unsecured Convertible Notes and Accrued Interest [Member] 2024 Unsecured Convertible Notes and Accrued Interest [Member] Debt Instrument [Axis] 2021 Notes [Member] 2025 Financing Note [Member] Officer and Director [Member] 2021 and 2025 Notes [Member] 2021, 2022, 2024, and 2025 Notes [Member] Short-Term Debt, Type [Axis] Convertible Notes Payable [Member] 2025 Notes [Member] Award Type [Axis] Consultant Options [Member] Location, Statement of Income, Balance [Axis] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Geographical [Axis] TENNESSEE Consolidated Entities [Axis] Visirose [Member] University of Miami [Member] Investment, Name [Axis] Legal Entity [Axis] Provectus [Member] Two Investors [Member] Segments [Axis] Clinical Stage Biotechnology Segment [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement [Table] Statement [Line Items] Assets Current Assets: Cash Prepaid expenses and other current assets Total Current Assets Equipment and furnishings, less accumulated depreciation of $120,479 and $120,013, respectively Operating lease right-of-use asset Total Assets Liabilities and Stockholders’ Deficit Current Liabilities: Accounts payable Accrued interest Other accrued expenses Notes payable Convertible notes payable Operating lease liability, current portion Total Current Liabilities Notes payable, non-current portion Operating lease liability, non-current portion Total Liabilities Commitments, contingencies, and litigations (Note 13) Stockholders’ Deficit: Preferred Stock value Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 420,279,879 shares issued and outstanding at March 31, 2026 and December 31, 2025 Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total Provectus Biopharmaceuticals, Inc., Stockholders’ Deficit Non-controlling interest in subsidiary Total Stockholders’ Deficit Total Liabilities and Stockholders’ Deficit Accumulated depreciation of equipment and furnishings Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, liquidation preference value Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Grant Revenue Operating Expenses: Research and development General and administrative Total Operating Expenses Total Operating Loss Other Expense: Interest expense Net Loss Net loss attributable to noncontrolling interest Net loss attributable to common stockholders Basic Loss Per Common Share Diluted Loss Per Common Share Weighted Average Number of Common Shares Outstanding - Basic Weighted Average Number of Common Shares Outstanding - Diluted Net Loss Other Comprehensive Income: Foreign currency translation adjustments Comprehensive Loss, net Comprehensive Loss attributable to non-controlling interest Comprehensive Loss attributable to controlling interest Balance Balance, shares Issuance of common stock of majority-owned subsidiary Conversion of 2025 Notes to Series D-1 Preferred Stock Conversion of 2025 Notes to Series D-1 Preferred Stock, shares Stock-based compensation: Amortization of stock options Net loss Other comprehensive income Conversion of 2022 Notes to Series D-1 Preferred Stock Conversion of 2022 Notes to Series D-1 Preferred Stock, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Non-cash operating lease expense Depreciation Changes in operating assets and liabilities Prepaid expenses and other current assets Accounts payable Unearned grant revenue Accrued interest Other accrued expenses Operating lease liability Net Cash Used In Operating Activities Cash Flows From Financing Activities: Proceeds from issuance of convertible notes payable Proceeds from issuance of convertible notes payable - related parties Proceeds from issuance of common stock of majority-owned subsidiary Repayment of short-term notes payable Net Cash Provided By Financing Activities Effect of exchange rates on cash and restricted cash Net Decrease In Cash and Restricted Cash Cash and Restricted Cash, Beginning of Period Cash and Restricted Cash, End of Period Cash and restricted cash consisted of the following: Cash Restricted cash Supplemental Disclosures of Cash Flow Information: Interest Income taxes Non-cash investing and financing activities: Conversion of 2022 Notes and related accrued interest to Series D-1 Preferred Stock Conversion of 2025 Notes and related accrued interest to Series D-1 Preferred Stock Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Organization, Nature of Operations and Basis of Presentation Liquidity and Going Concern Accounting Policies [Abstract] Significant Accounting Policies Payables and Accruals [Abstract] Other Accrued Expenses Debt Disclosure [Abstract] Convertible Notes Payable Notes Payable Related Party Transactions [Abstract] Related Party Transactions Prepaid Expenses And Other Current Assets Prepaid Expenses and Other Current Assets Equity [Abstract] Stockholders’ Deficit Leases Leases Government Assistance [Abstract] Grants License Transactions License Transactions Commitments and Contingencies Disclosure [Abstract] Commitments, Contingencies and Litigation Segment Reporting [Abstract] Segment Reporting Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Cash Concentrations Convertible Instruments Basic and Diluted Loss Per Common Share Segment Reclassifications Recently Issued Accounting Pronouncements Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares Schedule of Other Accrued Expenses Schedule of Convertible Notes Payable Schedule of Prepaid Expenses and Other Current Assets Schedule of Grant Date Value of Stock Options Valuation Assumptions Schedule of Option Activity Schedule of Stock Options Outstanding and Exercisable Schedule of Right-of-use Assets and Liabilities Schedule of Future Minimum Payments Under Non-cancellable Lease Schedule of Segment Reporting Information Working capital deficit Net loss Net cash used in operating activities Accounts payable and other accrued expenses Notes payable Convertible notes payable Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potentially dilutive shares Cash federally insured limits Cash uninsured amount Number of operating segments Number of reporting segments Accrued payroll and taxes Accrued vacation Accrued directors’ fees Accrued other expenses Total Other Accrued Expenses Short-Term Debt [Table] Short-Term Debt [Line Items] Balance as of January 1, 2026 Notes issued Principal converted Balance as of March 31, 2026 Maximum financing amount Loan interest rate Conversion price per share Common stock issuable upon conversion Proceeds from notes Principal amount outstanding Interest payable Interest expense Notes payable Director fees Accrued directors' fees Schedule Of Prepaid Expenses And Other Current Assets Deferred tax asset Prepaid insurance Prepaid rent Prepaid subscriptions Prepaid other Prepaid software Total Prepaid Expenses and Other Current Assets Risk free interest rate Expected term (years) Expected volatility Expected dividends Number of options outstanding, beginning balace Weighted average exercise price outstanding, beginning balance Weighted average remaining life in years, outstanding Aggregate intrinsic value outstanding, beginning balace Number of options exercisable, beginning balace Weighted average exercise price exercisable, beginning balance Weighted average remaining life in years, exercisable Aggregate intrinsic value exercisable, beginning balance Number of options outstanding, granted Weighted average exercise price outstanding, granted Weighted average remaining life, granted Aggregate intrinsic value outstanding, granted Number of options outstanding, ending balace Weighted average exercise price outstanding, ending balance Aggregate intrinsic value outstanding, ending balance Number of options exercisable, ending balace Weighted average exercise price exercisable, ending balance Aggregate intrinsic value exercisable, ending balance Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Options outstanding, exercise price Number of options outstanding Weighted average remaining life, exercisable Number of options exercisable Options intrinsic value Stock, Class of Stock [Table] Class of Stock [Line Items] Shares issued upon conversion Conversion of principal Conversion of accrued interest Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Stock options exercise price Number of stock options exercised Stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Leases Operating lease, expense Operating lease included in research and development expense Operating lease included in general and administrative expense Schedule Of Right-of-use Assets And Liabilities Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases Right-of-use assets obtained in exchange for lease obligations: Operating leases Weighted Average Remaining Lease Term: Operating leases Weighted Average Discount Rate: Operating leases Schedule Of Future Minimum Payments Under Non-cancellable Lease Remainder of 2026 2027 2028 Total lease payments Less: amount representing imputed interest Present value of lease liability Less: current portion Lease liability, non-current portion GrantsTable [Table] Grant revenue Grant value ScheduleLicenseTransactionsTable [Table] Investments Number of shares issued Ownership interest, percentage Net loss attributable to noncontrolling interest Segment Reporting [Table] Segment Reporting [Line Items] Research and development Clinical trial and research expenses Insurance Payroll and taxes Stock based compensation Rent and utilities Travel and entertainment Total research and development General and administrative Directors fees Donations Insurance Legal fees Other general and administrative expenses Payroll and taxes Professional fees Rent and utilities Stock based compensation Travel and entertainment Foreign currency transaction losses Total general and administrative Interest expense Subsequent Event [Table] Subsequent Event [Line Items] Notes principal and interest converted Series D-1 Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Series D-1 Preferred Stock [Member] Non cash operating lease expense. Conversion of notes and related accrued interest. 2025 Notes [Member] Working capital deficit. Computers and Office Equipment [Member] Grant Revenue [Policy Text Block] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Amount of expenses incurred but not yet paid classified as other, due within one year. Maximum financing arrangement amount. Knoxville, Tennessee [Member] Schedule Of Right Of Use Assets And Liabilities [Table Text Block] 2021 Notes [Member] Proceeds from grant award for study of animal cancer and dermatological. License Transactions [Text Block] Visirose [Member] Clinical Stage Biotechnology Segment [Member] Clinical trial and research expense. Insurance. Payroll and taxes. Stock based compensation research and development. Rent and utilities research and development. Directors fees. Donations. Rent and utilities. Travel and entertainment expenses. Prepaid Expenses And Other Current Assets Disclosure [Text Block] Prepaid subscriptions. Prepaid software. 2021 Unsecured Convertible Notes and Accrued Interest [Member] 2022 Unsecured Convertible Notes and Accrued Interest [Member] 2023 Unsecured Convertible Notes and Accrued Interest [Member] 2024 Unsecured Convertible Notes and Accrued Interest [Member] 2025 Financing Note [Member] Officer and Director [Member] 2021 and 2025 Notes [Member] 2021, 2022, 2024, and 2025 Notes [Member] Debt conversion debt interest amount. Share based compensation arrangement by share based payment award options grants in period weighted average grant date value. Consultant Options [Member] University of Miami [Member] Provectus [Member] Two Investors [Member] Stock issued during period value conversion of notes. Stock issued during period shares conversion of notes. Grant revenue. Operating lease included in research and development expense. Operating lease included in general and administrative expense. Granted term. Granted value. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Nonoperating Net Income (Loss) Attributable to Parent Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable, Trade Increase (Decrease) in Interest Payable, Net Increase (Decrease) in Other Accrued Liabilities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Repayments of Notes Payable Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash and Cash Equivalent Restricted Cash Lessee, Operating Leases [Text Block] License Transactions [Text Block] Notes Payable, Current Convertible Notes Payable [Default Label] Notes Payable [Default Label] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount General Insurance Expense Labor and Related Expense RentAndUtilities Travel and Entertainment Expense Gain (Loss), Foreign Currency Transaction, before Tax Interest Income (Expense), Operating